文献速递临床试验与 GCP流行病学与生物统计

向HIV感染者提供多种尼古丁替代产品以减少烟草使用(RETUNE):瑞士HIV队列研究内实用性随机试验方案

Offer of a menu of different nicotine substitute products to REduce Tobacco Use iN pEople living with HIV (RETUNE): a protocol for a pragmatic randomized trial within the Swiss HIV Cohort Study.
PubMed 文献 · Trials · 2026-04-08

RETUNE是一项在瑞士HIV队列研究内采用TwiCs设计的实用性、1:1随机、多中心优效性试验,计划招募972名每日吸烟超过1支且未使用任何替代产品的HIV感染者。干预组可免费选择电子烟、尼古丁袋或尼古丁贴片使用6个月,主要结局为6个月时过去7天自我报告的烟草戒断率,采用意向性分析。

要点

  • 在HIV感染者中采用TwiCs设计评估基于偏好的退出式(opt-out)戒烟干预。
  • 干预组可从电子烟、尼古丁袋和尼古丁贴片中免费选择任一产品使用6个月。
  • 主要结局为6个月时过去7天自我报告的烟草戒断率,采用意向性分析。

核心结论

  • RETUNE将阐明在HIV感染者中提供多种尼古丁替代产品菜单的退出式戒烟干预的有效性。

研究设计与样本

  • 实用性、1:1随机、多中心优效性临床试验,采用TwiCs设计嵌套于瑞士HIV队列研究。
  • 计划招募972名每日吸烟超过1支、未使用任何替代产品并签署随机化知情同意书的队列参与者。

主要发现

  • RETUNE于2025年2月开始招募,目前正在进行中。

关键数值与推荐

  • 主要结局为6个月时过去7天自我报告的烟草戒断率,采用调整地区、男男性行为、当前吸毒和基线每日吸烟支数的逻辑回归模型进行意向性分析。
  • 干预组可免费选择电子烟、尼古丁袋或尼古丁贴片使用6个月,或拒绝该提议。
  • 次要结局包括长期戒烟率和烟草相关健康结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Among people living with HIV, there has been a shift of focus from HIV-related health issues to cardiovascular diseases and cancer. For both, tobacco smoking is a major but insufficiently addressed etiological factor. Evidence from randomized trials suggests that nicotine substitute products such as e-cigarettes and nicotine patches can reduce tobacco smoking and its associated health burden. However, most previous smoking cessation trials primarily included people who are motivated to quit smoking and focused on testing a single nicotine substitute product. The effectiveness of offering a menu of nicotine substitute products to tobacco smokers regardless of their willingness to quit smoking ("opt-out" approach) is unknown. METHODS: Reduce tobacco use in people living with HIV in Switzerland (RETUNE, NCT06789692) is a pragmatic, 1:1 randomized, multicenter, superiority clinical trial using the Trials within Cohorts (TwiCs) design within the Swiss HIV Cohort Study. RETUNE assesses the effectiveness of offering a menu of different nicotine substitute products, namely electronic cigarettes, nicotine pouches, and nicotine patches, versus usual care. Cohort participants are eligible if they smoke more than one tobacco cigarette per day, do not use any of the substitute products, and have signed the randomization consent following the TwiCs design. Participants randomized to the intervention may choose any of the offered substitutes to be used free of charge for 6 months or decline the offer. Overall, we plan to recruit 972 participants. The primary outcome is tobacco abstinence at 6 months measured as participant-reported past 7-day prevalence abstinence. The primary outcome will be assessed in the intention-to-treat set using a logistic regression model adjusted for region, men having sex with men, current drug users, and number of cigarettes per day at baseline. Secondary outcomes are long-term smoking cessation rates and tobacco-associated health outcomes. DISCUSSION: RETUNE started recruitment in February 2025 and is currently ongoing. RETUNE using the TwiCs design will clarify the effectiveness of a preference-based opt-out smoking cessation intervention among people living with HIV. TRIAL REGISTRATION: Clinicaltrials.gov NCT06789692. Registered on January 17th, 2025. The manuscript is aligned with the registry. https://clinicaltrials.gov/study/NCT06789692?cond=NCT06789692&rank=1.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Schönenberger CM, Speich B, Zehnder ER, et al. Offer of a menu of different nicotine substitute products to REduce Tobacco Use iN pEople living with HIV (RETUNE): a protocol for a pragmatic randomized trial within the Swiss HIV Cohort Study. Trials. 2026. PMID: 41952225. doi:10.1186/s13063-026-09622-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。